Many published studies have investigated the association between CYP17 rs743572 polymorphism and benign prostatic hyperplasia (BPH) susceptibility but have yielded inconsistent results. Hence, we performed this meta-analysis using the multivariate statistic method to address a more precise association. Case-control or cohort studies with adequate genotype distribution or minor allele frequency (MAF) were identified by searching the PubMed, Embase, and Web of Science databases up to December, 2018. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the association between CYP17 rs743572 polymorphism and BPH susceptibility. Pooled MAFs of 13 studies were 37% in Caucasians and 56% in Orientals, respectively. Pooled results of 8 studies suggested that CYP17 rs743572 was not associated with the BPH susceptibility in the overall population (OR = 0.98, 95% CI: 0.80-1.20 for A2 vs. A1; OR = 0.99, 95% CI: 0.79-1.25 for A1/A2 vs. A1/A1; OR = 0.97, 95% CI: 0.62-1.53 for A2/A2 vs. A1/A1). Sensitivity analysis showed the results were robust. Subgroup analysis based on ethnicity suggested that, in Orientals, A2 allele carriers had a 28% lower risk of developing BPH compared with A1 allele carriers, and the risk of BPH is 47% lower in A2/A2 genotype carriers compared with A1/A1 genotype carriers. No significant association was observed in Caucasians. In conclusion, our study indicates a negative association between CYP17 and BPH in Orientals. However, due to limited sample size, the conclusion should be interpreted with caution.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6599153 | PMC |
| http://dx.doi.org/10.3389/fphys.2019.00774 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benign prostatic hyperplasia genetic variants in Asians.
Clin Chim Acta
January 2025
Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya 60115, Indonesia; Department of Urology, Jombang General Hospital, Jombang 61416, Indonesia.
The global prevalence of benign prostatic hyperplasia (BPH) is increasing annually, with a notably higher incidence in Asian populations. This condition can increase the risk of developing prostate cancer 2- to 12-fold, underscoring the critical need for comprehensive clinical guidelines and appropriate risk stratification testing. This review is the first to address the gap by focusing on genetic screening for risk stratification in Asians, followed by the development of pathophysiology based on the genetic variants identified.
View Article and Find Full Text PDFThe GG genotype of rs743572 in CYP17A1 gene regulating the decrease of T/E ratio can be an independent risk factor for MetS-BPH: a retrospective cohort study.
World J Urol
July 2024
Department of Urology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China.
Purpose: To confirm if the CYP17A1 gene regulates the ratio of T/E leading to MetS-BPH.
Methods: 824 men, aged 47-88 years, were recruited into this study through consecutive routine physical examination programs and long-term outpatient screening. Several parameters, including SNPs of CYP17A1 gene, total testosterone, estradiol, and the ratio of total testosterone to estradiol (T/E) were obtained for each participant.
The Effect of CYP2C19*2 (rs4244285) and CYP17 (rs743572) SNPs on Adriamycin and Paclitaxel based Chemotherapy Outcomes in Breast Cancer Patients.
Asian Pac J Cancer Prev
June 2024
Department of Molecular Biology and Genetics, Krishna Institute of Allied Sciences, Krishna Vishwa Vidyapeeth (Deemed to be University), Taluka-Karad, Dist- Satara, Pin-415 539, (Maharashtra) India.
Background: Cytochrome P450 (CYP) are phase I metabolizing enzymes involved in detoxification of chemotherapeutic agents. Among the CYP gene family, including CYP1A1, CYP1B1, CYP2C, CYP2D, CYP2E and CYP17, their significance in cancer susceptibility is well established. However, there remains limited understanding regarding the polymorphisms of CYP2C19*2 and CYP17 and their potential correlation with chemotherapy-induced toxicity reactions in breast cancer (BC) patients.
View Article and Find Full Text PDFTo elucidate the relationship between CYP17A1/CYP19A1/SHBG gene polymorphisms and PCOS susceptibility. We searched multiple databases from inception to December 2020 and meta analysis was conducted to elucidate the relationship between gene polymorphisms and PCOS risk. 26 studies were included, comprising 4860 PCOS and 4043 controls.
View Article and Find Full Text PDFThe single-nucleotide polymorphism rs743572 of CYP17A1 shows significant association with polycystic ovary syndrome: a meta-analysis.
Reprod Biomed Online
November 2021
Center for Reproductive Medicine, Henan Key Laboratory of Reproduction and Genetics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address:
Polycystic ovary syndrome (PCOS) is a multifactorial reproductive and endocrine disease, believed to be caused by aberrant steroid biosynthesis pathways involving cytochrome P450, 17α-hydroxylase (CYP17A1). This meta-analysis aimed to evaluate the association between CYP17A1 polymorphism rs743572 and PCOS risk. Studies on the CYP17A1 gene were retrieved by searching PubMed, Embase and Web of Science and statistical analyses were performed by STATA software.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!